KR20120044584A - Composition for the prevention and treatment of lipid related cardiovascular disease or obesity containing the extracts of allium fistulosum l as active ingredient - Google Patents

Abstract

PURPOSE: A composition containing Allium fistulosum L. extract for preventing and treating lipis-associated cardiovascular diseases or obesity is provided to suppress body fat and lipid synthesis. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity contains Allium fistulosum L. extract as an active ingredient. The extract is prepared using water, low alcohol of C1-C4, or mixture thereof. A method for preparing the extract comprises: a step of adding solvent to the dry Allium fistulosum L. and extracting; a step of filtering the extract; and a step of decompressing the extract. The low alcohol is ethanol or methanol. A health food for preventing and treating obesity contains the extract as an active ingredient. A pharmaceutical composition for preventing and treating lipid-associated cardiovascular diseases contains the extract as an active ingredient.

Description

Composition for the prevention and treatment of lipid related cardiovascular disease or obesity containing the extracts of Allium fistulosum L as active ingredient

The present invention is a total bag ( Allium fistulosum L.) It relates to a pharmaceutical composition or dietary supplement for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extract as an active ingredient.

Obesity is an excessive accumulation of fat in the body, the number of adipocytes (adipocyte) in the fat tissue increases or the fat cells increase in the size of fat cells increases. Obesity is becoming a more important disease factor because it causes major diseases such as diabetes, hypertension, hyperlipidemia, heart disease, arthritis, sexual dysfunction, and cancer (Must et al ., 1999).

Adipose tissue secretes adipocytokines such as TNF-a, adiponectin, leptin, etc., with a major role in fat storage. These adipocytokines are known to play an important role in metabolic diseases such as diabetes and obesity by being secreted from adipocytes and involved in insulin resistance, fat metabolism, and weight control. It is well known that as the abdominal fat increases, leptin concentration increases proportionally, while adiponectin secretion decreases, leading to diabetes, hypertension, and other cardiovascular diseases.

Therapies currently used include appetite suppressants, tropical death promoters, digestive absorption inhibitors, and hormone regulators that work by reducing food intake, regulating body metabolism, and increasing body fever. Appetite suppressants include adrenergic drugs, serotonergic drugs, and adrenergic / serotonin drugs, of which serotonergic drugs have been banned due to side effects of heart valve disease (Jae-Yeol Lee, 2006). Tropical death promoters include ephedrine-caffeine complexes and adipocyte 3 receptor agonists. Digestive and absorptive inhibitors include lipase inhibitors represented by Zenical and low-fat food additives called Olestra (Lee Jae-yeol, 2006). Many medications used to date have reported urinary phenomena and side effects such as anorexia, headaches, increased blood pressure, fatty stools, diarrhea, bloating, abdominal pain, etc. It is interpreted as the result of unvalidated products (Hong Soon-wook, 2007). Therefore, the development of new natural materials using traditional medicines, namely, herbal medicines, whose efficacy has been improved and their safety has been improved, is a problem that is continuously required in the present age.

In Oriental Medicine, Chongbaek (Allii Fistulosi Bulbus) refers to fresh scaly stem of the perennial herb ( Allium fistulosum L. ) of Liliaceae (KHP, 2007). Medicinal Detoxification and antibacterial action to reduce inflammation and boils, has been used for diarrhea, indigestion, abdominal cold and skin rash. In addition, it improves the cold constitution by improving blood circulation, it is effective in the pain caused by neuralgia, and has been used to prevent and treat colds by warming the body. However, no studies have been made or specified on the effect of baekbaek extract on obesity diseases.

Thus, the present inventors have chongbaek (Allium fistulosum L. ) Extracts reduce body fat as well as body fat, reduce blood lipid levels in obesity-induced animals, and reduce obesity by reducing the expression of fat-related genes, PPARγ, SREBP-1c and FAS, in the adipose tissue and adipocytokine in the blood. The present invention was completed by confirming the inhibitory effect.

Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. 1999. The disease burden associated with overweight and obesity. J Am Med Assoc 282: 1523-529. Jiang L, Zhang NX, Mo W, Wan R, Ma CG, Li X, Gu YL, Yang XY, Tang QQ, Song HY. 2008. Rehmannia inhibits adipocyte differentiation and adipogenesis. Biochem Biophys Res Commun 371 (2): 185-90. Shang W, Yang Y, Jiang B, Jin H, Zhou L, Liu S, Chen M. 2007. Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhancing PPARg2 and C / EBPa gene expression. Life Sciences 80: 618-625. Oben IE, Ngondi JL, Blum K. 2008. Inhibition of lrvingia gabonesis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponetin gene. Lipid in health and disease 7 (44): 1-6. Ono Y, Hattori Eri, Fukaya Y, Imai S, Ohizumi Y. 2006. Anti-obesity effect of Nelumbo nucifera leaves extract in mice and rats. Journal of Ethnopharmacology 106: 238-244. Ahima RS. 2006. Adipose tissue as an endocrine organ. Obesity (Silver Spring) (Suppl. 5) 242S-249S. Mi-Ja Kim and Hye Dyung Kim. 2009. Perilla leaf extract ameliorates obesity and dyslipidemia induced by high-fat diet. Phytother Res. Epub ahead of print. Hyounjeong Choi, Haekwan Eo, Kyoungcheol Park, Mirim Jin, Eun-Jin Park, Seon-Hee Kim, Jeong Euy Park, Sunyoung Kim. 2007. A water-soluble extract from Cucurbita moschata shows anti-obesity effects by controlling lipid metabolism in a high fat diet-induced obesity mouse model. Biochemical and Biophysical Research Communications. 359: 419-425. Michael A. Schnell, Christine Hardy, Melanie Hawley, Kathleen Joy Propert and James M. Wilson. 2002. Effect of blood collection technique in mice on clinical pathology parameters. Human gene therapy. 13: 155-162. Xiaoyan Sheng, Yuebo Zhang, Zhenwei Gong, Cheng Huang and Ying Qin Zang. 2008. Improved insulin resistance and lipid metabolism by cinnamon extract through activation of peroxisome proliferator-activated receptors. PPAR Research. Jaeyeol Lee. November 2006 issue. Development trends for obesity treatments. Fine Chemistry. Soon Wook Hong. 2007. Enhanced slimming of side effects of obesity drugs. KFDA Press Release. Sang-Sup Han, Hyun-Sook Han, Kyu-Hyuk Cho, Yang-Bum Kim, Jung-Wook Suh, Chang-Woo Song, 1994, Basic study on the age of Ktc: C57BL / 6 mice: weight, organ weight, hematology, blood biochemical changes and urine analysis. 10: 197-209. Food and Drug Administration. 2007. Korean Pharmacopoeia (9th Amendment), Korean Pharmacopoeia Herbal Medicine (KHB) Standard Collection (KHP).

An object of the present invention is a total bag ( Allium) fistulosum L.) It is to provide a composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extract as an active ingredient.

In order to achieve the above object, the present invention is a total bag ( Allium) fistulosum L.) It provides a pharmaceutical composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extract as an active ingredient.

In another aspect, the present invention provides a health food for the prevention and improvement of lipid-related cardiovascular disease or obesity containing a total extract as an active ingredient.

Total bag of the present invention (Allium fistulosum L.) extracts were administered to high-fat diets, such as weight loss, body fat reduction, fat cell size reduction, triglyceride, total cholesterol and low-density cholesterol (LDL-cholesterol) lowering. Obesity effect was also confirmed, and by reducing the expression of liposynthesis promoting genes PPARγ, SREBP-1c, FAS, blood leptin secretion and adiponectin secretion increase, the total white extract extracts lipid-related cardiovascular It can be effectively used in the development of a pharmaceutical composition for the treatment or prevention of diseases or obesity, or a dietary supplement for the purpose.

Figure 1 is a graph showing the inhibitory effect of weight gain by high fat diet by administration of baekbaek extract.
Figure 2 is a photograph showing the effect of reducing the size of adipocytes in subcutaneous adipose tissue by administration of baekbaek extract.
Figure 3 is a photograph showing the effect of reducing the size of adipocytes in post-peritoneal adipose tissue by administration of baekbaek extract.
Figure 4 is a photograph showing the effect of reducing the size of adipocytes in the epididymal fat tissue by administration of a total back extract.
Figure 5 is a photograph showing the effect of reducing the expression of PPARγ, SREBP-1c, and FAS in subcutaneous fat tissue by administration of baekbaek extract.
Figure 6 is a graph showing the effect of reducing leptin concentration and adaponectin concentration (adiponectin) concentration in the blood by administration of the extract.

Hereinafter, terms used in the present invention will be described.

As used herein, the term "prevention" means any action that inhibits lipid related cardiovascular disease or obesity by administration of a composition of the present invention.

As used herein, the terms "treatment" and "improvement" refer to all actions in which lipid-related cardiovascular disease or obesity is improved or beneficially altered by administration of a composition of the present invention.

As used herein, the term "administration" means providing a subject with a composition of the present invention in any suitable manner.

As used herein, the term “individual” refers to any animal, including humans, monkeys, dogs, goats, pigs, or rats, having suffered from lipid-related cardiovascular disease or obesity by administering the composition of the present invention.

As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat lipid-related cardiovascular disease or obesity at a reasonable benefit or risk ratio applicable to medical treatment, which indicates the severity of the obesity of the individual, Activity, sensitivity to drug, time of administration, route of administration and rate of release, duration of treatment, factors including drug used concurrently, and other factors well known in the medical arts.

Hereinafter, the present invention will be described in detail.

The present invention is a total bag ( Allium fistulosum L.) It provides a pharmaceutical composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extract as an active ingredient.

The baekbaek can be used without limitation, such as cultivated or commercially available.

The baekbaek extract is preferably prepared in the following steps, but is not limited thereto:

1) extracting the dried gross bag by adding an extraction solvent;

2) filtering the extract of step 1); And

3) concentrating the filtered extract of step 2) under reduced pressure.

In the above method, the extraction solvent of step 1) is preferably a solvent selected from water, an alcohol or a mixture thereof, preferably a C ₁ to C ₄ lower alcohol or a mixed solvent thereof, and a 70% aqueous ethanol solution is used. It is more preferable to use, but is not limited thereto. The amount of the extraction solvent is preferably 5 to 15 times the total bag dry weight, and more preferably 7 to 10 times, but not always limited thereto. The extraction method may be an extraction method such as hot water extraction, immersion extraction, reflux cooling extraction or ultrasonic extraction, but is not limited thereto. The extraction temperature is preferably 10 ℃ to 100 ℃ and more preferably room temperature. The extraction time is preferably 30 minutes to 3 hours, more preferably 1 to 2 hours, but is not limited thereto. The number of extraction is preferably 1 to 5 times, more preferably 3 times, but is not limited thereto.

In the above method, the reduced pressure concentration in step 3) is preferably a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably lyophilized, but is not limited thereto.

The present inventors measured weight and dietary intake changes by using obese-induced mice by high fat diet in order to examine the weight loss effect and the dietary intake inhibitory effect of baekbaek extract, significantly increased weight when administration of baekbaek extract It was confirmed that is reduced (see Table 1 and Figure 1).

In addition, the present inventors measured the weight of fat tissue derived from obesity-induced mouse by high-fat diet to determine the body fat reduction effect of the baekbaek extract, subcutaneous, peritoneal, epididymal fat tissue in all It was confirmed that the weight of adipose tissue was reduced (see Table 2). In addition, as a result of observing the effect of fat cell reduction using adipose tissue, when the total back extract was administered, it was confirmed that the size of fat cells decreased in both subcutaneous, peritoneal, and epididymal fat tissues (FIG. 2 to 2). See FIG. 4).

In addition, the present inventors performed a blood biochemical analysis using a serum derived from obesity-induced mice by a high-fat diet to determine the effect of reducing the total lipid content of the baekbaek extract, blood cholesterol total cholesterol when the baekbaek extract is administered (total cholesterol), triglyceride (triglyceride), low density (LDL-cholesterol) concentrations were found to significantly decrease (see Table 3).

In addition, the present inventors also found that the perioxisome proliferators activated receptorγ (PPARγ), sterol regulatory element binding protein (SREBP-1c) and major fats of liposynthesis-related transcription factors of baekbaek extracts. To investigate the effect of reducing fatty acid synthase (FAS) gene, a lipogenic enzyme, mRNA of PPARγ, SREBP-1c and FAS in the subcutaneous fat tissue derived from obesity-induced mouse by high-fat diet was RT- As a result of observing using PCR, it was confirmed that when the total back extract is administered, their expression is reduced in white fat (see FIG. 5).

In addition, the present inventors performed ELISA method using serum obtained from high fat diet-derived obesity-induced blood in order to determine the change in adipokines secretion in the blood of baekbaek extract, when administered baekbaek extract Leptin concentration in blood was significantly decreased, and adiponectin was confirmed to increase (see FIG. 6).

Therefore, the total back extract of the present invention suppresses weight gain and body fat increase by high fat diet, inhibits fat synthesis, triglyceride (total cholesterol), low cholesterol (LDL-cholesterol), which are blood lipids By lowering the), it improves the symptoms of obesity, it can be usefully used as an active ingredient in the prevention or treatment of lipid-related cardiovascular disease or obesity.

The composition of the present invention preferably comprises 0.1 to 90% by weight of the total bag extract based on the total weight of the composition, but is not limited thereto.

The composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

The composition of the present invention may be administered orally or parenterally, and when parenteral administration, it is preferable to select external or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method. It is not limited thereto.

The composition of the present invention can be used in the form of oral formulations, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods. have. Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose in the total extract of the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the composition is preferably administered at 0.0001 to 1 g / kg, preferably 0.001 to 200 mg / kg, but is not limited thereto. The administration may be administered once a day, or may be divided several times. The dose is not intended to limit the scope of the invention in any way.

In another aspect, the present invention provides a health food for the prevention and improvement of lipid-related cardiovascular disease or obesity containing a total extract as an active ingredient.

Chongbaek extract of the present invention inhibits weight gain and body fat increase by high fat diet, inhibits fat synthesis, triglyceride (total cholesterol), low-density cholesterol (LDL-cholesterol), a lipid in the blood Since it improves the symptoms of obesity by lowering, it can be usefully used as an active ingredient for the prevention or improvement of lipid-related cardiovascular disease or obesity.

There is no particular limitation on the kind of food. Examples of the foods include drinks, meat, sausages, breads, biscuits, rice cakes, chocolates, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, alcoholic beverages and vitamins. Combinations and the like, and include all of the health foods in the conventional sense.

The total back extract of the present invention can be added as it is to food or used with other foods or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to its use purpose (for prevention or improvement). In general, the amount of the extract in the health food can be added at 0.01 to 15% by weight of the total food weight, the health beverage composition can be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml. have. However, in the case of long-term intake for health and hygiene or health control purposes, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.

The health functional beverage composition of the present invention is not particularly limited to other ingredients except the total bag extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .

In addition to the above, the food of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the extract of the present invention may contain a fruit flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.

Hereinafter, the present invention will be described in detail by examples and production examples.

However, the following Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples and Preparation Examples.

Total back  Preparation of Extract

After extracting 200 g of baekbaek (Herb Herbal Medicine Co., Ltd.) with 10 times 70% EtOH three times under reflux for 3 hours, the filtrate was concentrated using a reduced pressure concentrator and then lyophilized to extract 31.79 g of a candidate pharmaceutical extract. Was prepared.

High fat diet induced animal model Anti-obesity  Efficacy Experiment

<2-1> experimental animals and breeding conditions

Experimental animals received 4 weeks-old male C57BL / 6J mice from the center experimental animals, the temperature 20-22 ℃, relative humidity 40-60%, 1 hour in the animal nursery room of the Korea Institute of Oriental Medicine that the contrast is controlled every 12 hours Purified to adapt to the environment for a week. The diet was fed during the period of purifying, and the diet and drinking water were freely ingested during the experiment.

<2-2> Production of Obese Animal Model Induced by High Fat Diet

High-fat diets (Rodent diet D12492, Research Diets, New Brunswick, NJ) were purchased from Central Experimental Animals Inc. and consisted of 20% protein, 20% carbohydrate and 60% fat.

The experimental group consisted of 4 groups: normal diet (ND), which received normal feed, normal saline (ND), normal fat (ND), high fat diet, high fat diet (HFD), high fat diet The drug treatment group (400 mg / kg / day) receiving the extract, and the positive control group (15.6 mg / kg) receiving Xenical (obesity treatment drug, Xenical) while ingesting high fat feed, consisted of 7-8 for each group. Random distributions to horses were used for the experiment. All test substances were administered orally every day. The amount of administration was 10 ml / kg, and the amount of administration for each subject was administered based on the measured body weight twice a week for 6.5 weeks.

<2-3> Effects of Chongbaek Extract on Weight Gain and Dietary Intake

The body weight and dietary intake of the test animals were measured by electronic balance (GP5202, Sartorius, Germany) twice a week at a time. Feed efficiency was calculated as the ratio of weight gain to feed intake.

As a result, as shown in Figure 1, the high-fat diet group steadily increased body weight compared to the normal diet group. However, when the total back extract was administered to the high-fat diet group, body weight decreased steadily after 3 weeks compared to the high-fat diet group. The positive control group lost weight significantly from 6 weeks. There was no difference in dietary intake compared to the high-fat diet group (Table 1).

Body weight gain of the high-fat diet group was significantly increased compared to the normal diet group when the body weight was measured after the end of the experiment, and when the total back extract and the positive control group were administered to the high-fat diet group, the weight was higher than the high-fat diet group. The increase was decreased (p <0.05).

In addition, the feed efficiency (FER) was significantly increased in the high-fat diet group compared to the normal diet group, and the total diet was significantly decreased compared to the high-fat diet group (p <0.05).

group Weight gain
(g / mouse) Feed intake
(g / day) Feed Efficiency (FER) + Normal group (ND) 3.84 ± 0.23 4.65 ± 0.29 0.84 ± 0.06 Control (HFD)     9.81 ± 0.59 ###     2.50 ± 0.07 ###     3.87 ± 0.17 ### Positive control group (zenical)    6.61 ± 0.30 ** 3.77 ± 0.87     1.92 ± 0.31 *** Total back extract of the present invention   7.46 ± 0.63 * 2.59 ± 0.13   2.40 ± 0.44 *

Significant difference between normal group (ND) and control group (HFD): ### p <0.001; And

Significant differences between the control group (HFD) and the positive control or total bag extract administration groups: * p <0.05, ** p <0.05, * p <0.001.

<2-4> Total back  Body Fat Weight Reduction Effect of Extracts

Example 2 After the completion of the experiment, the weight of the white adipose tissue was measured in order to confirm the effect of reducing body fat weight by the total bag extract.

As a result, the weight of the subcutaneous, epididymis, and peritoneal fat tissues was increased in the high-fat diet group compared to the normal diet group, while the weight loss of the total white extract and the positive control group was reduced compared to the high-fat diet group (Table 2). .

group White adipose tissue (mg / g body weight) Subcutaneous fat Epididymal region Post-peritoneal fat Normal group (ND)       7.28 ± 1.09 10.50 ± 2.10 4.82 ± 1.93 Control (HFD)    33.85 ± 2.36 ###     52.65 ± 2.66 ###   20.18 ± 0.61 ### Positive control group (zenical)  21.09 ± 1.05 *   35.40 ± 1.26 *  13.79 ± 1.59 ** Total back extract of the present invention  23.89 ± 2.94 *   41.64 ± 2.52 * 14.52 ± 1.61 *

Significant difference between normal group (ND) and control group (HFD): ### p <0.001; And

Significant differences between the control group (HFD) and the positive control or total bag extract administration groups: * p <0.05, ** p <0.01, * p <0.001.

<2-5> Total back  Fat Cell Reduction Effect of Extracts

Example <2-3> After completion of the experiment, in order to confirm the histopathological adipocyte reduction effect of the total back extract, the adipose tissue was fixed in 10% neutral buffered formalin solution for 24 hours, and the fixed liver tissue was frozen and sectioned. Oil (Oil red) staining was carried out, adipose tissue was paraffin embedded (paraffin embedding) to make a block 4㎛ thickness and stained with Hematoxylin-eosin (Hematoxylin-eosin (H & E)) and observed under a microscope.

As a result, as shown in Figures 2 to 4, the fat diet was increased in the high-fat diet group compared to the normal diet group, while the total back extract administration group was confirmed that the size decreased compared to the high-fat diet group and the positive control group ( 2 to 4).

<2-6> Hematological Indicator Measurement

Example 2 After the experiment was completed, the blood collected from the mouse was left at room temperature for 30 minutes and then centrifuged at 3000 rpm for 15 minutes in order to confirm the effect of reducing blood lipid content of the total bag extract. The blood serum biochemical analyzer was used to measure the content of glucose, total cholesterol, triglyceride, low density cholesterol (LDL-cholesterol) and high density cholesterol (HDL-cholesterol).

As a result, as shown in Table 3, the total cholesterol, triglycerides, low-density cholesterol concentrations of blood lipids were significantly decreased when the total back extract was administered as compared to the high-fat diet group (p <0.05).

group
Total cholesterol
(mg / dL)
Triglycerides
(mg / dL) LDL-
cholesterol
(mg / dL) HDL-
cholesterol
(mg / dL) Normal group (ND) 110.3 ± 3.8  68.0 ± 6.5  4.8 ± 0.1  74.0 ± 2.5 Control (HFD)     166.3 ± 2.0 ###   88.7 ± 11.2    5.9 ± 0.3 #  76.5 ± 4.9 Positive control group (zenical) 159.3 ± 7.3  82.0 ± 6.1  6.0 ± 0.5  88.9 ± 4.2 The
Baekbaek extract   148.4 ± 3.9 *    48.2 ± 3.8 *     4.5 ± 0.2 **  71.7 ± 1.7

Significant difference between normal group (ND) and control group (HFD): * p <0.05, ### p <0.001; And

Significant difference between control (HFD) and total bag extract administration groups: * p <0.05, ** p <0.01.

<2-7> Lipid Synthesis Regulator PPAR γ, SREBP -1c and FAS  Observed changes in expression

Example 2 After the experiment, the extracted white adipose tissue was extracted with total RNA in tissue using easyBLUE solution (Intron). RT-PCR was performed using a One Step-RT-PCR kit (Qiagen) with 1 μg of total RNA and 10 uM of gene specific primers. RT-PCR products were isolated by electrophoresis on 1.2% agarose gel and stained with ethidium bromide (EtBr) to observe mRNA expression of PPARγ, SREBP-1c and FAS genes. GAPDH was used as a control. The sequence of PPARγ, SREBP-1c, and FAS primers is as follows.

PPARγ: forward-5'-CCCTGGCAAAGCATTTGTAT-3 '(SEQ ID NO: 1),

          reverse-5'-GAAACTGGCACCCTTGAAAA-3 '(SEQ ID NO: 2);

SREBP-1c: forward-5'-AGCTC AAAGACCTGGTGGTG-3 '(SEQ ID NO: 3),

          reverse-5'-TCATGCCCTCCATAGACACA-3 '(SEQ ID NO .: 4); And

FAS: forward-5'-CGCACCGGCTACCAAGCCAA-3 '(SEQ ID NO: 5),

          reverse-5'-GCTTCCCGGGTTG CCCTGTC-3 '(SEQ ID NO: 6).

As a result, as shown in Figure 5, the expression of PPARγ, SREBP-1c and FAS genes in white subcutaneous fat tissue increased by the high fat diet compared to the control group, the expression of these genes decreased when the total back extract was administered .

<2-8> In the blood Leptin ( leptin ), Adiponectin ( adiponectin ) Change in secretion amount

Serum obtained from blood was measured for leptin and adiponectin secretion using the ELISA method.

As a result, as shown in Figure 6, leptin concentration in the high-fat diet group was higher than the normal diet group, leptin concentration in the total bag extract administration group was reduced to a significant level (p <0.05). In addition, the blood adiponectin concentration was significantly increased in the total bag extract administration group compared to the high-fat diet group (p <0.05) (Fig. 6).

< Manufacturing example  1> Preparation of Pharmaceutical Formulations

<1-1> Powder  Produce

2 g of baekbaek extract of Example 1

1 g lactose

The above components were mixed and packed in airtight bags to prepare powders.

<1-2> Preparation of Tablet

100 mg total extract of Example 1

Corn starch 100 mg

100 mg of milk

2 mg magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

&Lt; 1-3 > Preparation of capsules

100 mg total extract of Example 1

Corn starch 100 mg

100 mg of milk

2 mg magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

&Lt; 1-4 >

1 g of ginseng extract of Example 1

Lactose 1.5 g

1 g of glycerin

Xylitol 0.5 g

After mixing the above components, it was prepared to be 4 g per ring according to a conventional method.

<1-5> Preparation of granules

150 mg of baekbaek extract of Example 1

Soybean Extract 50mg

Glucose 200 mg

600 mg of starch

After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, which were then filled into fabrics.

Production Example 2 Preparation of Food

The food containing the extract of the present invention was prepared as follows.

<2-1> Production of flour food

0.5 to 5.0 parts by weight of the total bag extract of Example 1 was added to the flour, and the mixture was used to prepare bread, cake, cookies, crackers and noodles.

<2-2> Preparation of Soups and Gravys

0.1 ~ 5.0 parts by weight of the total bag extract of Example 1 was added to soups and gravy to prepare a health-promoting processed meat products, noodles soup and gravy.

<2-3> ground Beef  Produce

10 parts by weight of the total bag extract of Example 1 was added to the ground beef to prepare a ground beef for health promotion.

<2-4> Production of Dairy Products

5-10 parts by weight of the total bag extract of Example 1 was added to milk, and various milk products such as butter and ice cream were prepared using the milk.

<2-5> Preparation of Wire

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.

Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.

The total bag extract of Example 1 was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a sprayer and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.

The grains, seeds, and the extract of Example 1, which were prepared above, were prepared by combining the following ratios:

Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

Total back extract of Example 1 (3 parts by weight),

Ganoderma lucidum (0.5 parts by weight), and

Sulfur (0.5 part by weight).

< Manufacturing example  3> Manufacturing of beverage

<3-1> Health drink  Produce

Instant sterilization by homogeneously combining 5 g of ginseng extract of Example 1 with subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%). Then it was prepared by packaging in a small packaging container such as glass bottles, plastic bottles.

<3-2> Preparation of Vegetable Juice

Vegetable juice was prepared by adding 5 g of the total bag extract of Example 1 to 1,000 ml of tomato or carrot juice.

<3-3> Preparation of Fruit Juice

1 g of the total bag extract of Example 1 was added to 1,000 ml of apple or grape juice to prepare a fruit juice.

The present invention can be effectively used in the development of a pharmaceutical composition or dietary supplement for the treatment or prevention of lipid-related cardiovascular disease or obesity containing a total back extract as an active ingredient.

<110> Korea institute oriental medicine <120> Composition for the prevention and treatment of lipid related          cardiovascular disease or obesity containing the extracts of          Allium fistulosum L. as active ingredient <130> 10p-10-06 <160> 6 <170> KopatentIn 1.71 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> PPAR gamma forward primer <400> 1 ccctggcaaa gcatttgtat 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> PPAR gamma reverse primer <400> 2 gaaactggca cccttgaaaa 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> SREBP 1c forward primer <400> 3 agctcaaaga cctggtggtg 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> SREBP 1c reverse primer <400> 4 tcatgccctc catagacaca 20 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> FAS forward primer <400> 5 cgcaccggct accaagccaa 20 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> FAS reverse primer <400> 6 gcttcccggg ttgccctgtc 20

Claims (12)

Total back ( Allium fistulosum L. ) Pharmaceutical composition for the prevention and treatment of obesity containing the extract as an active ingredient.
The pharmaceutical composition for preventing and treating obesity of claim 1, wherein the extract is extracted with water, C ₁ to C ₄ lower alcohols, or a mixture thereof.
3. The pharmaceutical composition for preventing and treating obesity, according to claim 2, wherein the lower alcohol is ethanol or methanol.
Health food for the prevention and improvement of obesity containing baekbaek extract as an active ingredient.
The method of claim 4, wherein the extract is water, C ₁ to C ₄ lower alcohol or a mixture thereof, characterized in that the health food for the prevention and improvement of obesity.
[6] The health food for preventing and improving obesity, according to claim 5, wherein the lower alcohol is ethanol.
Pharmaceutical composition for the prevention and treatment of lipid-related cardiovascular disease containing a total back extract as an active ingredient.
The pharmaceutical composition for preventing and treating lipid-related cardiovascular disease according to claim 7, wherein the extract is extracted with water, C ₁ to C ₄ lower alcohols, or a mixture thereof.
The pharmaceutical composition for preventing and treating lipid-related cardiovascular disease according to claim 8, wherein the lower alcohol is ethanol.
Health food for the prevention and improvement of lipid-related cardiovascular disease containing baekbaek extract as an active ingredient.
The method of claim 10, wherein the extract is water, C ₁ to C ₄ low alcohol or a mixture of them, characterized in that the health food for the prevention and improvement of lipid-related cardiovascular diseases.
12. The health food for preventing and improving lipid-related cardiovascular disease according to claim 11, wherein the lower alcohol is ethanol.

Images